HACE1 Inhibitors
The chemical class of HACE1 inhibitors, as detailed above, encompasses a range of compounds that influence cellular signaling pathways and processes where HACE1 plays a regulatory role. These inhibitors do not directly target HACE1 but rather modulate the pathways and processes where HACE1 is involved, thereby indirectly affecting its function. The majority of these compounds are kinase inhibitors targeting various points in critical signaling pathways such as the EGFR pathway, the RAS/RAF/MEK/ERK pathway, and the mTOR pathway. For example, Erlotinib and Gefitinib, both EGFR inhibitors, affect the EGFR signaling pathway where HACE1 is known to be involved in EGFR ubiquitination. By inhibiting EGFR, these compounds indirectly alter the ubiquitination dynamics of EGFR, which can influence HACE1's regulatory role. Similarly, compounds like Sorafenib and Dabrafenib target the RAS/RAF/MEK/ERK pathway, wherein HACE1's E3 ligase activity plays a part in regulating pathway components through ubiquitination. The inhibition of key kinases in this pathway can, therefore, indirectly modulate HACE1's function.
Another significant group within this class includes mTOR inhibitors such as Rapamycin, Temsirolimus, and Everolimus. These compounds disrupt the mTOR signaling pathway, which is vital for cell growth and survival. HACE1 is implicated in cellular stress responses, and the modulation of mTOR signaling can indirectly influence HACE1's activity in these responses. Additionally, proteasome inhibitors like Bortezomib represent a different approach, where the alteration of proteasomal degradation pathways affect HACE1's function in protein ubiquitination and degradation. In summary, the chemical class of HACE1 inhibitors consists of compounds that indirectly influence HACE1's activity by targeting various cellular signaling pathways and processes where HACE1 has a regulatory role. These inhibitors, through their action on different kinases and cellular mechanisms, modulate the dynamics of pathways and processes, thereby influencing HACE1's function indirectly.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that impedes the EGFR signaling pathway. HACE1 has been implicated in the ubiquitination of EGFR, thus, the inhibition of EGFR by Erlotinib can lead to altered EGFR ubiquitination dynamics and indirectly affect HACE1's role in this process. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which disrupts the mTOR signaling pathway. This pathway is integral for cell growth and survival. By inhibiting mTOR, Rapamycin can lead to changes in cellular stress responses, potentially influencing HACE1's activity in cellular stress regulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor, particularly targeting RAF kinases in the RAS/RAF/MEK/ERK pathway. Since HACE1 is involved in the regulation of this pathway through its E3 ligase activity, Sorafenib's action can indirectly influence HACE1's regulatory role. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR inhibitor, similar to Erlotinib. It blocks EGFR tyrosine kinase, which can indirectly affect HACE1's involvement in EGFR ubiquitination and degradation, altering the downstream signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. While it doesn’t directly target HACE1, it alters proteasomal degradation pathways in which HACE1 might be involved, thereby potentially affecting HACE1's function in protein ubiquitination and degradation. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor, targeting the MEK1/2 in the RAS/RAF/MEK/ERK pathway. Its action can indirectly influence HACE1’s regulatory role in this pathway, as HACE1 is involved in ubiquitination related to this signaling cascade. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is another mTOR inhibitor. By impeding mTOR signaling, it can indirectly modulate HACE1's activity, particularly in cellular responses to stress and survival signals. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a selective MEK1/2 inhibitor, affecting the RAS/RAF/MEK/ERK pathway. HACE1’s involvement in this pathway through its E3 ligase activity can be indirectly influenced by Trametinib's action. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 is a CDK4/6 inhibitor, affecting cell cycle progression. HACE1, involved in cell cycle regulation through ubiquitination processes, can be indirectly influenced by the altered cell cycle dynamics due to Palbociclib. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib is a MEK inhibitor targeting MEK1/2 in the RAS/RAF/MEK/ERK pathway. It can indirectly affect HACE1's function in ubiquitination and regulation within this pathway. | ||||||